Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $164.90 | Total: $824.50 |
| 1 | 10 | $139.68 | Total: $1,396.80 |
| 1 | 25 | $118.34 | Total: $2,958.50 |
| 1 | 50 | $100.88 | Total: $5,044.00 |
| 1 | 100 | $87.30 | Total: $8,730.00 |
Overview
Plogosertib (CYC140) is an orally active, selective, potent, and ATP-competitive PLK1 inhibitor with an IC50 value of 3 nM.Plogosertib exhibits antiproliferative and anticancer activity and can be used for the study of solid and hematologic tumors. and hematologic tumors.
Chemical Properties
| Molecular Formula | C34H48N8O3 |
| Molecular Weight | 616.797 |
| CAS Numbers | 1137212-79-3 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | O=C1C2(CN(C=3C(N1C)=CN=C(NC4=C(OC)C=C(C(N[C@@H]5CC[C@H](CC5)N6CCN(C)CC6)=O)C=C4)N3)C7CCCC7)CC2 |
Storage and Handling
0C Short Term, -20C Long Term
References
Sylvie Moureau, et al. Abstract 4178 The novel PLK1 inhibitor, CYC140 Identification of pharmacodynamic markers, sensitive target indications and potential combinations. Cancer Res [2017] 77 [13_Supplement] 4178.